Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD476 once-daily versus Asacol twice-daily for maintenance of remission in ulcerative colitis
2004-004184-29Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Takeda. Primary endpoint: Percentage of subjects in endoscopic remission at month 6. Started Feb 2005; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2004-004184-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004184-29.